Case-Based Review: newly diagnosed glioblastoma

被引:14
|
作者
Johnson, Derek R. [1 ,2 ]
Fogh, Shannon E. [3 ]
Giannini, Caterina [4 ]
Kaufmann, Timothy J. [5 ]
Raghunathan, Aditya [4 ]
Theodosopoulos, Philip V. [6 ]
Clarke, Jennifer L. [6 ,7 ]
机构
[1] Mayo Clin, Dept Neurol, 200 First St SW, Rochester, MN 55905 USA
[2] Mayo Clin, Div Med Oncol, Rochester, MN USA
[3] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA 94143 USA
[4] Mayo Clin, Dept Lab Med & Pathol, Rochester, MN USA
[5] Mayo Clin, Dept Radiol, Rochester, MN USA
[6] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA
[7] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA
关键词
chemotherapy; glioblastoma; radiation; surgery; temozolomide;
D O I
10.1093/nop/npv020
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Glioblastoma (WHO grade IV astrocytoma) is the most common and most aggressive primary brain tumor in adults. Optimal treatment of a patient with glioblastoma requires collaborative care across numerous specialties. The diagnosis of glioblastoma may be suggested by the symptomatic presentation and imaging, but it must be pathologically confirmed via surgery, which can have dual diagnostic and therapeutic roles. Standard of care postsurgical treatment for newly diagnosed patients involves radiation therapy and oral temozolomide chemotherapy. Despite numerous recent trials of novel therapeutic approaches, this standard of care has not changed in over a decade. Treatment options under active investigation include molecularly targeted therapies, immunotherapeutic approaches, and the use of alternating electrical field to disrupt tumor cell division. These trials may be aided by new insights into glioblastoma heterogeneity, allowing for focused evaluation of new treatments in the patient subpopulations most likely to benefit from them. Because glioblastoma is incurable by current therapies, frequent clinical and radiographic assessment is needed after initial treatment to allow for early intervention upon progressive tumor when it occurs.
引用
收藏
页码:106 / 121
页数:16
相关论文
共 50 条
  • [41] CHEMORADIOTHERAPY OF NEWLY DIAGNOSED GLIOBLASTOMA WITH INTENSIFIED TEMOZOLOMIDE
    Weiler, Markus
    Hartmann, Christian
    Wiewrodt, Dorothee
    Herrlinger, Ulrich
    Gorlia, Thierry
    Baehr, Oliver
    Meyermann, Richard
    Bamberg, Michael
    Tatagiba, Marcos
    von Deimling, Andreas
    Weller, Michael
    Wick, Wolfgang
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2010, 77 (03): : 670 - 676
  • [42] Guidelines for the treatment of newly diagnosed glioblastoma: introduction
    Jeffrey J. Olson
    Timothy Ryken
    Journal of Neuro-Oncology, 2008, 89 : 255 - 258
  • [43] Guidelines for the treatment of newly diagnosed glioblastoma: introduction
    Olson, Jeffrey J.
    Ryken, Timothy
    JOURNAL OF NEURO-ONCOLOGY, 2008, 89 (03) : 255 - 258
  • [44] Radiosensitizers in the temozolomide era for newly diagnosed glioblastoma
    Mathen, Peter
    Rowe, Lindsay
    Mackey, Megan
    Smart, DeeDee
    Tofilon, Philip
    Camphausen, Kevin
    NEURO-ONCOLOGY PRACTICE, 2020, 7 (03) : 268 - 276
  • [45] Interstitial photodynamic therapy for newly diagnosed glioblastoma
    Quach, Stefanie
    Schwartz, Christoph
    Aumiller, Maximilian
    Foglar, Marco
    Schmutzer, Michael
    Katzendobler, Sophie
    El Fahim, Mohamed
    Forbrig, Robert
    Bochmann, Katja
    Egensperger, Rupert
    Sroka, Ronald
    Stepp, Herbert
    Ruehm, Adrian
    Thon, Niklas
    JOURNAL OF NEURO-ONCOLOGY, 2023, 162 (01) : 217 - 223
  • [46] Use of focal radiation for newly diagnosed glioblastoma
    Sills, Allen K.
    Redmond, Allen
    Jackson, Mary
    Dubal, Nilesh
    NEURO-ONCOLOGY, 2006, 8 (04) : 490 - 490
  • [47] A randomized trial of bevacizumab for newly diagnosed glioblastoma
    Schiff, David
    Huse, Jason
    Wen, Patrick
    NEURO-ONCOLOGY, 2014, 16 (06) : 769 - 770
  • [48] MULTIGENE PREDICTOR OF OUTCOME IN NEWLY DIAGNOSED GLIOBLASTOMA
    Aldape, Kenneth D.
    Shoostari, Nasrin
    McDonald, Jon M.
    Colman, Howard
    NEURO-ONCOLOGY, 2009, 11 (02) : 218 - 219
  • [49] The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline
    Velazquez Vega, Jose E.
    Brat, Daniel J.
    Ryken, Timothy C.
    Olson, Jeffrey J.
    JOURNAL OF NEURO-ONCOLOGY, 2020, 150 (02) : 143 - 164
  • [50] The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline
    José E. Velázquez Vega
    Daniel J. Brat
    Timothy C. Ryken
    Jeffrey J. Olson
    Journal of Neuro-Oncology, 2020, 150 : 143 - 164